Background {#Sec1}
==========

Following hip fracture, as many as 25--30 % of patients have reportedly been unable to return to their previous living situation, while 28 % of those who were ambulatory before fracture are unable to walk 12 months postoperatively \[[@CR1], [@CR2]\]. This loss of function is probably due in part to muscle wasting and loss of muscle strength, i.e. sarcopenia \[[@CR3]\]. Protein-energy malnutrition, which is common in elderly hip fracture patients \[[@CR4], [@CR5]\], most likely contributes to sarcopenia and loss of ambulatory capacity. The prevalence of low muscle mass among hip fracture patients has been shown to be between 20-85 %, depending on age and gender \[[@CR6], [@CR7]\].

Besides the age-related loss of muscle mass, the hip fracture trauma, presurgical fasting and hip fracture-associated immobilization cause adverse changes in body composition. As much as 5--6 % of muscle mass may be lost during the first year following fracture \[[@CR8], [@CR9]\]. This should be compared with the reported age-related loss of muscle mass, which seems to be fairly constant at a yearly rate of 1--2 % after age 50 \[[@CR10]\]. Increased muscle wasting following hip fracture is likely to be one of several factors with a bearing on poor outcome like reduced function \[[@CR1], [@CR11]\]. The benefit of nutritional supplementation following hip fracture is not conclusive and sometimes the opposite is reported, as in the latest Cochrane Collaboration Review \[[@CR12]\]. This review concluded that nutritional supplementation may potentially have beneficial effects, such as reducing general complications. However, only one randomized trial has previously evaluated the effects of protein and energy-rich supplementation on body composition as measured by DXA following hip fracture \[[@CR13]\]. This study showed that muscle mass was protected from catabolism when protein supplementation was combined with an anabolic drug.

The hypothesis of the present study was that protein and energy-rich supplementation provided together with bisphosphonate may be able to limit muscle catabolism, have beneficial effects on muscle strength and thereby also improve health-related quality of life (HRQoL) following hip fracture in the elderly. Secondary specific objectives were to study the relationships between fat-free mass index (FFMI), appendicular lean mass index (aLMI) and handgrip strength (HGS).

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The study included 79 patients, 56 women (71 %) and 23 men (29 %), mean age 79 (SD 9, range 61--96 years), who were admitted to one of the four university hospitals in Stockholm, Sweden, with the diagnosis of femoral neck or trochanteric fracture. As described previously, \[[@CR14]\] inclusion criteria were age 60 or older, without severe cognitive impairment, ambulatory before fracture, living independently. From the beginning we included patients with BMI less than 26 kg/m^2^ since BMI of 26 is the average BMI in community dwelling men and women in Sweden aged \> 70 years. Due to the difficulties in recruiting patients the inclusion cut-off was increased to 28 kg/m^2^.

Patients who had received bisphosphonate treatment in the year prior to admission, or who had pathological fracture, malignancy, or bone metabolic disorder were excluded. Further exclusion criteria were abuse of alcohol, drugs, or the presence of an obvious psychiatric disorder, dysphagia, esophagitis, gastric ulcer, lactose intolerance, diabetes mellitus with nephropathy or retinopathy, and active iritis or uveitis. Patients with abnormal liver and kidney function tests were also excluded.

Study design and intervention {#Sec4}
-----------------------------

The primary purpose of this randomized multicenter trial was to study the effects of combined therapy with bisphosphonate and protein-rich nutritional supplementation after hip fracture on body composition, HGS and HRQoL. The outcome on bone mineral density of the same study population was recently reported \[[@CR14]\]. To summarize the study design, patients were randomized into three treatment groups using sealed envelopes. Randomization was carried out by a research nurse, in collaboration with the trial physician in charge at each hospital. All patients received calcium 1 g and vitamin D 800 IE; specifically, cholecalciferol (Calcichew-D3®; Takeda Pharmaceutical Company Limited, Osaka, Japan) divided into two daily doses for 12 months. The nutritional supplementation group (protein + energy = N group) received a 200 ml package twice daily, each containing 20 g of protein and 300 kcal (Fresubin®, Fresenius Kabi, Bad Homburg, Germany). This supplement was given for the first six months following hip fracture and was combined with risedronate (Optinate® Septimum; Sanofi AB, Warner Chilcott, Weiterstadt, Germany), 35 mg once weekly for 12 months. The second group (B) received risedronate alone, 35 mg once weekly for 12 months. The controls (C) received only calcium and vitamin D for 12 months. Treatment began as soon as the patients were medically stable after surgery, able to take orally administered medications and able to sit upright for one hour after intake of bisphosphonates. Due to potential compliance problems, as well as anticipated effects on muscle mass and function within 6 months, it was decided to cease the nutritional supplementation after 6 months. Blood samples were collected in the morning of the first weekday on the ward. DXA and all calculations were carried out during the hospital stay and patients were re-examined at 6 and 12 months. All patients received conventional rehabilitation aimed at restoring the ability to walk.

Approval for the study was obtained from the local Ethics Committee at Karolinska University Hospital, Stockholm. The study was conducted in accordance with the Helsinki Declaration. Before inclusion all participants provided written consent to participate in the study.

Measurements {#Sec5}
------------

Body composition, including lean mass composed of muscle, visceral organs and water (LM), fat mass (FM) and bone mineral content (BMC), was measured by whole body dual-energy X-ray absorptiometry (DXA) using either Hologic (Hologic, Inc Waltham, MA, USA) or GE Lunar (Madison, WI, USA) densitometers. The sum of LM and BMC represents fat-free mass (FFM). To normalize for body size, FFM was divided by height squared to calculate fat-free mass index (FFMI, kg/m^2^). Fat mass index (FMI, kg/m^2^) was calculated analogously \[[@CR15]\]. Cut-offs for low FFMI were \<17 kg/m^2^ for men and \<15 kg/m^2^ for women \[[@CR16]\]. Mathematically, the sum of FFMI and FMI equals BMI. Cut-offs for FFMI were based on currently available European reference values for body composition in a Swiss population, rounded to the nearest integer \[[@CR16]\]. Thus, FFMI \<10th percentile of the reference population was considered to be low \[[@CR15], [@CR16]\]. Patient height, weight and body mass index (BMI) were monitored. Height was measured in supine position. Weight was calculated from the sum of LM, FM and BMC obtained from the DXA measurements and defined as total body mass (kg). Data on lean mass from DXA of legs and arms were used to calculate appendicular skeletal muscle mass (kg). For the purposes of this assessment, the lean mass of the un-fractured leg multiplied by 2 was used at baseline to avoid overestimation in the fractured leg due to postoperative edema \[[@CR6]\]. An appendicular lean mass index (aLMI, kg/m^2^) was calculated by dividing appendicular lean mass (aLM, kg) by height squared \[[@CR17]\]. Cut-off points used for low aLMI were ≤7.23 kg/m^2^ for men and ≤5.67 kg/m^2^ for women \[[@CR18]\].

Handgrip strength (HGS, kg) was measured in the dominant hand by hand dynamometer, (JAMAR 5030 J1; Sammons Preston, Rolyan, Bolingbrook, IL, USA) with the patient in a sitting position; the highest value of three was recorded. HGS measured by the Jamar dynamometer has been shown to have good reproducibility (r \> 0.80) and reliability (r = 0.98) \[[@CR19], [@CR20]\]. Cut-off points used for low HGS strength were \<30 kg in men and \<20 kg in women \[[@CR3]\].

Ocurrence of sarcopenia was defined according to the recent suggestion from the European Working Group on Sarcopenia in Older People (EWGSOP) \[[@CR3]\], as a combination of low aLMI and reduced HGS in accordance with the above-mentioned cut-off values.

HRQoL was defined using the EQ-5D descriptive system and converted to a single summary index for each patient (EQ-5D~index)~ \[[@CR21]\]. An EQ-5D~index~ of 0.00 indicated the worst possible state of health and a value of 1.00 the best. According to the Short Portable Mental Status Questionnaire (SPMSQ), only patients without severe cognitive impairment (≥3 correct answers on 10 questions) were included in the study \[[@CR22]\]. General physical health was assessed by the attending anesthesiologist before surgery according to the American Society of Anesthesiologists (ASA) classification \[[@CR23]\].

Biochemical measures considered relevant for this study were analyzed according to the standard hospital laboratory procedure in plasma (P) or serum (S) at baseline, 6 and 12 months, including blood hemoglobin (B-Hgb, g/L), c-reactive protein (S-CRP, mg/L), albumin (P-Alb, g/L), alanine aminotransferase (S-ALT, μkat/L), aspartate aminotransferase (S-AST, μkat/L), P-creatinine (μmol/L) and S-thyroid-stimulating hormone (S-TSH, mE/L). Glomerular filtration rate (GFR, ml/min) was estimated from P-Cystatin C (mg/L). As a nutritional biochemical marker, serum levels of insulin-like growth factor-I (S-IGF-I, μg/L) were analyzed by radioimmunoassay \[[@CR24]\]. Because of the age dependence of S-IGF-I, the values were also expressed as SD scores calculated from the regression of IGF-I values in a healthy reference population. SD scores ± 2SD were considered to be within the age reference range \[[@CR25], [@CR26]\].

Statistical methods {#Sec6}
-------------------

Statistical calculations were performed using SPSS version 22.0 for Windows (IBM, SPSS Statistics). Mean, standard deviation, median, range and percentage were used for descriptive purposes.

Univariate correlations at baseline between FFMI and aLMI, and between aLMI and HGS were analyzed using Pearson correlation coefficient and Spearman's rank correlation coefficient, respectively. Non-parametric tests were used to analyze EQ-5D~index~ data. For biochemical measurement analyses, both parametric and non-parametric tests were used depending on distribution and type of variables. Chi-square test and Fisher's exact test were used to compare the proportions of patients with sarcopenia in the treatment groups.

Statistical analyses for the outcome measures body composition, FFMI, FMI and HGS were carried out using covariance analysis (ANCOVA). The ANCOVA analyses included the exposure measures treatment groups and sex as fixed factors. Age and baseline values for FFMI, FMI and HGS were included as covariates. To have a sort of sensitivity analysis of the results, the complete cases population was analyzed and results for this population were presented. To have a complete and objective evaluation of data, the results of the analysis for the intention-to-treat (ITT) population were also presented. Missing data were processed for each of the outcome measures according to the hot-deck method \[[@CR27]\]. This method replaces missing data with randomly assigned values taken from individuals that are stratified according to sex and age. ITT analyses were performed using the database with imputed data.

Calculations revealed that a sample size of 40 patients per group was required to detect a difference in lean mass between groups (power = 80 %, a = 0.05). However, the study was closed after 4 years due to difficulties in recruiting patients and the study was switched to an exploratory design.

Results {#Sec7}
=======

The distribution of patients at inclusion and at follow-up is shown in the flow chart (Fig. [1](#Fig1){ref-type="fig"}). No significant difference in baseline characteristics was found between the groups (Table [1](#Tab1){ref-type="table"}). Low FFMI was found in 22 of 79 (28 %) and low aLMI in 32 of 79 (40 %) patients at baseline. There was a positive correlation between FFMI and aLMI, r = 0.92, P \<0.01. The total number of patients with sarcopenia, i.e. with both low aLMI and reduced HGS, was 16 of 75 (21 %) at baseline (missing HGS data *n* = 4); the corresponding figures at 6 and 12 months were 24 and 29 %, respectively, with no significant difference between groups over the observation period.Fig. 1Flow chart of participantsTable 1Baseline characteristics of all participants and by intervention groupAll patients (*n* = 79)Group N (*n* = 26)Group B (*n* = 28)Group C (*n* = 25)Age, mean (SD)79 (9)81 (8)80 (9)78 (11)Age, median (range)81 (61--96)82 (62--93)82 (63--94)75 (61--96)Gender, female n (%) Women56 (71)19 (73)18 (64)19 (76) Men23 (29)7 (27)10 (36)6 (24)Type of fracture n (%) Femoral neck33 (42)10 (38)12 (43)11 (44) Trochanteric46 (58)16 (62)16 (57)14 (56)Surgical method n (%) Internal fixation69 (87)23 (88)25 (89)21 (84) Arthroplasty10 (13)3 (12)3 (11)4 (16)Time to surgery n (%) Within 24 hours43 (54)13 (16)17 (22)13 (16)  \> 24 to 48 hours36 (46)13 (16)11 (14)12 (15)ASA 1--2 n (%)60 (76)20 (25)22 (28)18 (23)ASA 3--4 n (%)19 (24)6 (9)6 (8)7 (8)Body mass,kg mean (SD)63.0 (12.3)61.4 (9.8)66.9 (13.3)60.2 (12.8) Women58.7 (10.0)60.2 (9.8)60.7 (10.0)55.4 (9.8) Men73.3 (11.3)64.7 (9.5)78.2 (11.2)75.4 (8.7)BMI, kg/m^2^ mean (SD)23.0 (3.0)22.7 (3.4)24.0 (2.9)22.4 (2.6) Women22.8 (3.1)23.0 (3.5)23.9 (3.1)21.7 (2.5) Men23.5 (2.8)21.8 (3.3)24.1 (2.8)24.5 (1.2)FFMI, kg/m^2^ mean (SD)16.1 (2.0)15.6 (1.9)16.8 (2.0)16.0 (2.0) Women15.3 (1.4)15.0 (1.6)15.9 (1.4)15.1 (1.0) Men18.1 (2.0)17.1 (2.0)18.3 (2.0)18.8 (1.7)FMI, kg/m^2^ mean (SD)6.9 (2.5)7.1 (2.9)7.2 (2.4)6.4 (2.0) Women7.5 (2.5)8.0 (2.6)8.0 (2.4)6.6 (2.2) Men5.5 (1.8)4.8 (2.4)5.8 (1.7)5.7 (1.1)aLMI, kg/m^2^6.2 (0.9)6.0 (0.8)6.5 (0.9)6.2 (1.0) Women5.9 (0.7)5.8 (0.8)6.1 (0.6)5.8 (0.6) Men7.0 (1.0)6.6 (80.8)7.1 (1.0)7.5 (0.9)Handgrip strength, kg, median (range)20 (6--64)20 (6--63)22 (6--64)20 (8--58) Women18 (6--38)18 (6--32)18 (6--28)17 (8--38) Men36 (20--64)24 (20--33)45 (28--64)40 (23--58)EQ-5D~index~ mean, (SD)0.85 (0.21)0.84 (0.22)0.84 (0.25)0.88 (0.12)S-IGF-I, μg/L, median, (range)87 (27--239)72 (30--169)93 (30--207)87 (27--239)S-IGF-I age matched SD- score−0.6−1.1−0.1−0.8P-Alb g/L, median, (range)34 (26--44)34 (27--42)34 (26--44)34 (26--44)B-Hbg g/L, median, (range)124 (90--156)124 (97--149)128 (103--156)119 (90--153)S-CRP mg/L, median (range)3 (0--257)4 (0--136)2 (0--253)8 (0--257)P-Creatinine μmol/L,median, (range)71 (37--174)69 (37--136)74 (47--118)71 (49--174)S-ALAT, μkat/L, median, (range)0.41 (0.10--8.82)0.36 (0.10--8.82)0.40 (0.12--3.02)0.45 (0.19--1.57)S-ASAT, μkat/L, median, (range)0.65 (0.22--2.42)0.66 (0.23--1.61)0.62 (0.35--2.42)0.60 (0.22--1.60)S-TSH, mE/L, median (range)1.5 (0.1--9.3)1.7 (0.4--8.5)1.4 (0.8--8.5)1.4 (0.4--9.3)Group N, received nutritional supplementation, bisphosphonate, calcium and vitamin D3; B, received bisphosphonate, calcium and vitamin D; C, controls, treated with calcium and vitamin D. Body mass (lean mass, fat mass and bone mineral content); ASA, the American Society of Anesthesiologists classification; BMI, body mass index; FFMI, fat free mass index; FMI, fat mass index; aLMI, appendicular lean mass index; EQ-5D~index~, the 5-Dimentional Scale of the HRQoL; S-IGF-I, serum-insulin growth factor-I; P-Alb, plasma-albumin; B-Hbg, blood-Hemoglobin; S-CRP, serum-C-reactive protein; P-creatinine, plasma creatinine; S-ALT, serum alanine aminotransferase; S-AST, serum aspartate aminotransferase; S-TSH, serum thyroid-stimulating hormone. Baseline characteristics showed no significant difference between the groups

Treatment adherence with nutritional supplementation {#Sec8}
----------------------------------------------------

As described previously \[[@CR14]\], 11 of 18 patients presenting at the final follow-up reported consuming only half the prescribed intake of protein and energy drink (200 ml) giving an average of 0.32 g protein per kg bodyweight during the treatment period of 6 months. The remaining 7 patients did take the prescribed daily dose (200 ml *x*2) giving 0.70 g protein per kg bodyweight. There were no significant difference between those who were compliant to the prescription and those who took half prescribed supplement regarding outcome of total body mass, aLMI, FFMI, FMI or HGS at the two follow-ups (data not shown).

Effect on body composition {#Sec9}
--------------------------

An overall loss of body mass and FFM occurred during 6 and 12 months after fracture, with no significant difference between groups (Table [2](#Tab2){ref-type="table"}). There were tendencies for increased FMI and a greater drop in FFMI and aLMI in the N group (Table [2](#Tab2){ref-type="table"}). The ITT analyses confirmed this trend, showing no drop in FMI in the N group at 6 months (*P* = 0.01) and a greater drop of FFMI in the N group compared with the other two groups at 6 and 12 months (*P* \<0.001 and *P* = 0.006, respectively).Table 2Outcome of body composition components, handgrip strength, health-related quality of life and biochemical measurementsMonthsAll patientsGroup NGroup BGroup C*p*-valueBody mass, kg (SD)^a^0-6−2.1 (3.5)−2.0 (3.5)−3.0 (3.8)−1.2 (3.2)0.29^b^0-12−1.6 (4.0)−1.8 (3.0)−2.2 (4.6)−0.9 (4.1)0.69FFM, kg (SD)^a^0-6−1.5 (2.5)−2.4 (2.0)−1.3 (3.2)−1.0 (1.9)0.09^b^0-12−1.6 (2.7)−2.2 (2.5)−1.4 (3.2)−1.3 (2.2)0.41FM, Kg (SD)^a^0-6−0.6 (2.9)+0.4 (2.3)−1.7 (3.6)−0.2 (2.1)0.06^b^0-12−0.2 (3.4)+0.4 (2.1)−0.7 (4.4)−0.1 (3.0)0.64aLM, kg (SD)^a^0-6−0.1 (1.6)−0.7 (1.4)+0.3 (1.9)+0.02 (1.4)0.06^b^0-6−0.2 (1.6)−0.4 (1.5)−0.02 (2.0)−0.2 (1.4)0.40FFMI, kg/m^2^ (SD)^a^0-6−0.6 (0.9)−0.9 (0.7)−0.4 (1.2)−0.4 (0.8)0.08^b^0-12−0.6 (1.0)−0.8 (0.9)−0.5 (1.2)−0.5 (0.8)0.31FMI^a^0-6−0.2 (1.1)0.1 (0.8)−0.6 (1.4)−0.1 (0.8)0.06kg/m^2^ (SD)^b^0-12−0.1 (1.2)0.1 (0.8)−0.3 (1.6)−0.1 (1.1)0.62aLMI^a^0-60.0 (0.6)−0.2 (0.5)+0.1 (0.7)0.0 (0.6)0.03kg/m^2^ (SD)^b^0-12−0.1 (0.6)−0.2 (0.5)0.0 (0.7)−0.1 (0.5)0.30HGS, kg (SD)^c^0-61.4 (4.8)2.6 (4.7)−0.3 (4.0)2.2 (5.4)0.09^d^0-12−1.0 (5.8)−0.06 (6.6)−3.0 (6.1)−0.2 (5.7)0.22EQ-5D~index~ (SD)^c^60.77 (0.23)0.75 (0.32)0.76 (0.20)0.78 (0.19)0.57^d^120.74 (0.23)0.76 (0.22)0.70 (0.25)0.75 (0.24)0.60S-IGF-I,μg/L (range)6124 (31--280)124 (39--265)135 (45--280)117 (31--236)0.3912119 (45--310)111 (45--205)137 (68--310)129 (66--202)0.35S-IGF-I, SD score60.40.40.60.10.42120.20.10.70.40.58P-Alb, g/L (range)638 (24--47)37 (28--46)38 (24--42)39 (33--47)0.481238 (28--46)40 (29--46)37 (34--45)39 (33--45)0.31B-Hgb, g/L (range)6134 (107--171)136 (110--171)134 (113--160)132 (107--154)0.8912136 (109--162)136 (109--162)134 (115--153)136 (115--151)0.84S-CRP, mg/L (range)60 (0--48)4 (0--32)0 (0--48)0 (0--17)0.15121 (0--21)2 (0--21)1 (0--8)1 (0--6)0.24P-Creatinine, μmol/L (range)671 (41--173)67 (41--123)76 (55--117)72 (50--173)0.381273 (41--173)67 (43--127)80 (57--128)71 (49--118)0.19Group N = protein and energy supplementation for 6 months, and risedronate, vitamin D and calcium for 12 months, B = risedronate, vitamin D and calcium for 12 months, C = vitamin D and calcium for 12 months. Body mass (lean mass, fat mass and bone mineral content); FFM, fat free mass; FM, fat mass; aLM, appendicular lean mass; FFMI, fat free mass index; FMI, fat mass index; HGS, handgrip strength; EQ-5D~index~, the 5-Dimentional Scale of the HRQoL; S-IGF-I, serum-insulin growth factor-I; P-Alb, plasma-Albumin; B-Hgb, blood-Hemoglobin; S-CRP, serum-C-reactive protein; P-Creatinine, plasma-Creatinine. Data are given as mean (SD) or median (range). ^a^Patients analyzed 0--6 months in group N, *n* = 19; group B, *n* = 25; group C, *n* = 24. ^b^Patients analyzed 0--12 months in group N, *n* = 18; group B, *n* = 25; Group C; *n* = 23. ^c^Patients analyzed 0--6 months in group N, *n* = 20; group B, *n* = 25; group C, *n* = 25. ^d^Patients analyzed 0--12 months in group N, *n* = 18; group B, *n* = 25; group C, *n* = 21

Effect on handgrip strength {#Sec10}
---------------------------

A positive correlation was found between aLMI and HGS at baseline (r~s~ = 0.47, *P* \< 0.01, Fig. [2](#Fig2){ref-type="fig"}), and at 6 (r~s~ = 0.61, *P* \< 0.01) and 12 months (r~s~ = 0.64, *P* \< 0.01). A trend for improved HGS was seen (complete cases, table [2](#Tab2){ref-type="table"}), but was not confirmed by ITT analysis. Intra-group analysis showed a significant increase in HGS within the N group during the first 6 months (*P* = 0.04), while this change was not significant for the other two groups.Fig. 2Relationship between appendicular lean mass index and handgrip strength at baseline

Effect on HRQoL {#Sec11}
---------------

The EQ-5D~index~ decreased from 0.85 (SD 0.21) at baseline to 0.77 (SD 0.23) at 6 months and 0.74 (SD 0.23) at 12 months for all patients. Inter-group analysis showed no differences (Table [2](#Tab2){ref-type="table"}). Intra-group analysis between 0--12 months showed a significant decrease in the EQ-5D~index~ for the C and B groups (*P* = 0.03 and *P* = 0.01, respectively), but not for the N group (*P* = 0.22) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Outcome of EQ-5D index in different treatment groups at baseline, 6 and 12 months postoperatively. Group C, Controls = vitamin D and calcium for 12 months; B = risedronate, vitamin D and calcium for 12 months; *N* = protein and energy supplementation for 6 months, and risedronate, vitamin D and calcium for 12 months

Biochemical measures {#Sec12}
--------------------

The biochemical measures showed no significant differences between groups at baseline (Table [1](#Tab1){ref-type="table"}), or at the two follow-ups (Table [2](#Tab2){ref-type="table"}). Average S-IGF-I and age-adjusted SD score were within normal range in all groups at baseline (Table [1](#Tab1){ref-type="table"}). S-IGF-I increased between baseline and 6 months in all groups without inter-group differences (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec13}
==========

This study evaluated the potential for protein and energy supplementation combined with bisphosphonate to preserve muscle mass when prescribed to elderly hip fracture patients over an extended period of time. However, this intervention, which was administered together with vitamin D and calcium, had no positive effect on handgrip strength, HRQoL, or lean mass, when compared with administration of bisphosphonate along with vitamin D and calcium supplementation, or just vitamin D and calcium supplementation alone after hip fracture. Thus, none of the study hypotheses could be confirmed. The results of the intention-to-treat analysis were in line with those of the complete-cases analysis. However, intra-group analysis did show a positive effect on HRQoL and improved HGS in the nutritional supplementation group. These intra-group differences may indicate that the study was underpowered to answer the questions addressed. Post-hoc analyses showed that at least 135 patients (vs the 79 in this study) would be needed to reach statistical significance between groups for effect on HGS. Furthermore, because emerging evidence suggests that vitamin D has positive effects on muscle strength, administration of vitamin D to all groups may have negated any significant differences in treatment effects among groups \[[@CR28]\].

The finding of postoperative catabolism with loss of lean mass despite protein-rich nutritional supplementation following hip fracture is consistent with a previous study \[[@CR13]\]. Loss of lean mass in the prior study was 1.6 kg (SD 1.5) and in the present 2.1 kg (SD 2.6) in the first year after fracture, despite nutritional supplementation in both studies. The prior study showed that lean mass was preserved during the first 6 months only among patients who received an anabolic steroid in addition to supplementation \[[@CR13]\]. Loss of lean mass following hip fracture has been reported at 5--6 % during the first year \[[@CR8], [@CR9]\], which is in line with the observed loss of 5.2 % in our study, even though our patients received nutritional support for 6 months. It could be debated if the nutritional supplementation should have been lasting longer than six months, however the idea was to attenuate lean mass loss during the first six postoperative months when the effects of trauma and surgery on weight and lean mass is most pronounced. Considering compliance, six months was also a reasonable time for an intervention study with nutritional supplementation. As far as we know there has not been any nutritional intervention trials earlier persisting longer than six months for hip fracture patients. One explanation for the lack of significant benefits may be that the prolonged catabolic state, with its metabolic, hormonal and inflammatory response to trauma and surgery, results in an accelerated and prolonged breakdown of muscle protein \[[@CR29], [@CR30]\]. This negative energy balance in response to injury may also have a negative impact on the ability of patients to benefit from nutrients \[[@CR29], [@CR31]\]. Many hip fracture patients suffer from poor nutrition and a negative energy balance prior to admission for hip fracture \[[@CR5]\]. One previous study showed no improvement in nutritional status, despite adequate energy intake postoperatively among patients who were undernourished prior to hip fracture surgery \[[@CR32]\]. Recently, there has been increased focus on the composition of protein supplementation. Indications have emerged that certain essential amino acids, specifically the branched-chain amino acid leucine, which is abundant in whey protein or its metabolite hydroxy-methyl-butyrate (HMB), may have anabolic effects in addition to the purely nutritional effects \[[@CR33], [@CR34]\]. This study used a traditional balanced mix of proteins. Further studies are needed to assess whether more explicit beneficial effects could be attained by use of these specific protein compounds.

The proportion of patients with sarcopenia did not differ statistically among the groups over the observation period. The prevalence of sarcopenia in total was 21 % at baseline, and 24 and 29 %, respectively after 6 and 12 months. This confirms earlier reports of a catabolic situation that persists during the first year after hip fracture \[[@CR35]\]. The proportion of hip fracture patients with low aLMI at baseline has previously been reported to be 47 %, compared with 40 % in the present study \[[@CR7]\]. This slight difference may be due to the selection of a relatively healthy group of patients in the present study and also to the use of different normative data. We used the aLMI reference values from a study by Newman et al. \[[@CR18]\], while the previous study used normative aLMI data derived from a Japanese population \[[@CR36]\]. We found a higher proportion of patients with low aLMI at both 6 and 12 months than at baseline, but no previous studies with aLMI results at one year following hip fracture are available for comparison with our findings.

A trend toward preserved FMI was seen at 6 months in the nutritional supplementation group, which was significantly supported by the intention-to-treat analysis, and was also seen in a previous study with nutritional support prior to elective hip surgery \[[@CR37]\]. A possible explanation for preserved FMI, albeit not FFMI, through nutritional supplementation in the present study might be the impact that lack of resistance training during rehabilitation could have on fat metabolism. Exercise programs with resistance training combined with nutritional supplementation have been reported to result in lean mass gain \[[@CR38]\]. Still an increase in FMI may indicate some anabolic effects of the supplementation. The interactions between fat mass, fat free mass and function need to be better understood.

We noted improved HGS in the protein and energy supplementation group between baseline and 6 months. A similar improvement in HGS after 3 months of nutritional supplementation has been shown earlier in elderly patients following hospitalization due to acute illness, as well as in chronically-ill outpatients \[[@CR39], [@CR40]\]. Strength or physical performance is a complex parameter that relates to more than just mass, meaning that muscle function may improve even when muscle mass remains unaffected \[[@CR41], [@CR42]\]. This may help explain our findings in the nutritional supplementation group showing a trend toward preserved HGS, but not FFMI, as well as the modest relationship between HGS and aLMI found in our analysis. We chose to measure HGS in the present study since a strong association has been shown between HGS and muscle strength in the legs, and also because HGS actually predicts mobility better than muscle mass \[[@CR43]\].

HRQoL decreased in all groups and failed to reach pre-fracture levels by 12 months, consistent with an earlier study following hip fracture \[[@CR44]\]; however, intra-group analysis showed less of a drop in the nutritional supplementation group. Preservation of HRQoL after hip fracture has not previously been seen following supplementation alone, but has been demonstrated when supplementation is combined with an anabolic steroid \[[@CR13]\].

Certain limitations in this study need to be acknowledged. As mentioned above, one major limitation is the small number of study subjects, which may lead to type 2 errors, i.e. the risk of missing a true positive effect. The difficulties of including large numbers of hip fracture patients in intervention studies with nutritional supplementation are generally acknowledged \[[@CR12]\]. However, in our opinion this study might make a substantial contribution if meta-analysis is undertaken in the future. Other limitations include the high attrition rate and suboptimal adherence in the nutritional supplementation group, both of which have been encountered in earlier studies \[[@CR45], [@CR46]\]. The use of different devices of DXA measurements inflict uncertainties on the validity of the results. Still, this is a problem multi-center studies are usually facing and difficult to avoid. Further, intervention was first initiated postoperatively, which may have reduced the ability to counter the effects of the catabolic process that was already underway before surgery. The strength and novelty of this study lie in the DXA measurements of body composition with assessment of changes in fat-free mass, fat mass, appendicular muscle mass, strength and HRQoL, to evaluate the response to oral nutritional supplementation following hip fracture in the elderly. Other attributes include assessment of appendicular lean mass index together with HGS to determine the prevalence of sarcopenia in the study population not just at baseline, but also postoperatively for one year. The randomized design and the long 12-month follow-up period were additional strengths.

Conclusions {#Sec14}
===========

In this fairly small study, supplementation with protein and energy combined with conventional rehabilitation were not able to preserve lean mass following hip fracture any better than vitamin D and calcium alone, or combined with bisphosphonates. There were no inter-group differences concerning effects on HGS or HRQoL, but intra-group improvement in HGS and a positive effect on HRQoL were seen in the nutritional supplementation group.

Additional file {#Sec15}
===============

Additional file 1:**CONSORT checklist for RCT protocols.** (DOC 38 kb)

aLM

:   appendicular Lean Mass

aLMI

:   appendicular Lean Mass Index

ASA

:   The American Society of Anesthesiologists Classification

BMC

:   Bone Mineral Content

BMI

:   Body Mass Index

DXA

:   Dual-energy X-ray Absorptiometry

EQ-5D

:   The 5-Dimentional Scale of the HRQoL

EWGSOP

:   European Working Group on Sarcopenia in older People

FFM

:   Fat-Free Mass

FFMI

:   Fat-Free Mass Index

FM

:   Fat Mass

FMI

:   Fat Mass Index

HGS

:   Handgrip Strength

HRQoL

:   Health-Related Quality of Life

ITT

:   Intention-To-Treat

LM

:   Lean Mass

SPMSQ

:   Short Portable Mental Status Questionnaire
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